Drug Trial Radar · NCT06830044
Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
500
Planned (sponsor's estimate)
Start
Mar 3, 2025
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Vanda PharmaceuticalsIndustry
- Sponsor type
- Industry
- First posted
- Feb 17, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Conditions
- Major Depressive Disorder (MDD)
Interventions
MilsaperidoneDrug
Oral milsaperidone
PlaceboDrug
Oral placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in Montgomery-Asberg Depression Rating Scale (MADRS)Time frame: 6 weeks
Locations
53 sites in 4 countries. Site status is shown where the registry gives one.
Vanda Investigational Site
Phoenix, Arizona · Recruiting
Vanda Investigational Site
Little Rock, Arkansas · Recruiting
Vanda Investigational Site
Garden Grove, California · Recruiting
Vanda Investigational Site
Orange, California · Recruiting
Vanda Investigational Site
Redlands, California · Recruiting
Vanda Investigational Site
San Jose, California · Recruiting
Vanda Investigational Site
Walnut Creek, California · Recruiting
Vanda Investigational Site
Colorado Springs, Colorado · Recruiting
Vanda Investigational Site
Fort Myers, Florida · Recruiting
Vanda Investigational Site
Miami, Florida · Active not recruiting
Vanda Investigational Site
Miami, Florida · Recruiting
Vanda Investigational Site
Tampa, Florida · Active not recruiting
Vanda Investigational Site
Snellville, Georgia · Recruiting
Vanda Investigational Site
Chicago, Illinois · Recruiting
Vanda Investigational Site
Carmel, Indiana · Recruiting
Vanda Investigational Site
Boston, Massachusetts · Recruiting
Vanda Investigational Site
Saint Charles, Missouri · Recruiting
Vanda Investigational Site
Las Vegas, Nevada · Recruiting
Vanda Investigational Site
New York, New York · Recruiting
Vanda Investigational Site
New York, New York · Recruiting
Vanda Investigational Site
Staten Island, New York · Recruiting
Vanda Investigational Site
Charlotte, North Carolina · Recruiting
Vanda Investigational Site
Cincinnati, Ohio · Recruiting
Vanda Investigational Site
Media, Pennsylvania · Active not recruiting
Vanda Investigational Site
Houston, Texas · Recruiting
Vanda Investigational Site
Plano, Texas · Recruiting
Vanda Investigational Site
Richardson, Texas · Recruiting
Vanda Investigational Site
Witchita Falls, Texas · Recruiting
Vanda Investigational Site
Bellevue, Washington · Recruiting
Vanda Investigational Site
Kardzhali, Bulgaria · Recruiting
Vanda Investigational Site
Pleven, Bulgaria · Recruiting
Vanda Investigational Site
Plovdiv, Bulgaria · Recruiting
Vanda Investigational Site
Sofia, Bulgaria · Recruiting
Vanda Investigational Site
Sofia, Bulgaria · Recruiting
Vanda Investigational Site
Sofia, Bulgaria · Recruiting
Vanda Investigational Site
Targovishte, Bulgaria · Recruiting
Vanda Investigational Site
Varna, Bulgaria · Recruiting
Vanda Investigational Site
Vratsa, Bulgaria · Recruiting
Vanda Investigational Site
Brno, Czechia · Recruiting
Vanda Investigational Site
Pilsen, Czechia · Recruiting
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.